The ability to simply get full coverage from insurers, for very sick lymphoma patients, without weeks or months of haggling about off-label benefits, is worth its weight in gold, to Gilead and its Kite Pharma unit. Trust that. Here's the latest, from Friday -- [with earnings due next week]:
. . .Gilead’s Kite unit announced on Friday that the U.S. Food and Drug Administration approved a label update for its CAR-T therapy Yescarta, removing a limitation that prevented its use in a subset of patients with a rare form of lymphoma.
The revised prescribing information removes Yescarta’s previously limited use in patients with relapsed or refractory ((R/R)) primary central nervous system lymphoma, a rare type of lymphoma that mainly affects the brain and spinal cord. . . .
Now you know -- and my favorite exotic chocolates tasting season is upon us. . . starting Monday, I will frequent the best bespoke chocolatiers of this fine city, and bring home nightly treasures -- to try, with hot coffee or ice-cold milk. Grin!
नमस्ते
2 comments:
Check out latest on Substack.
Updated: I've made your Substack the third icon in my blogroll at left. I re-upped the 2008 era graphic too! It is yours, as always for the wide world. End updated portion....
Will do, my friend -- a lil' saddened by Lindsey Vonn's tough wipe-out. Game over.
Namaste....
Post a Comment